Aurinia Pharmaceuticals Inc.: diluted earnings per share

What this measure means

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Exact concept: us-gaap:EarningsPerShareDiluted. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Related financial histories

• Aurinia Pharmaceuticals Inc.: total assets
• Aurinia Pharmaceuticals Inc.: total liabilities
• Aurinia Pharmaceuticals Inc.: stockholders equity
• Aurinia Pharmaceuticals Inc.: cash and cash equivalents
• Aurinia Pharmaceuticals Inc.: net income or loss
• Aurinia Pharmaceuticals Inc.: operating cash flow
• Aurinia Pharmaceuticals Inc.: contract revenue excluding tax
• Aurinia Pharmaceuticals Inc.: financing cash flow
• Aurinia Pharmaceuticals Inc.: investing cash flow
• Aurinia Pharmaceuticals Inc.: retained earnings or deficit
• Aurinia Pharmaceuticals Inc.: basic weighted-average shares
• Aurinia Pharmaceuticals Inc.: diluted weighted-average shares
• Aurinia Pharmaceuticals Inc.: basic earnings per share
• Aurinia Pharmaceuticals Inc.: income tax expense or benefit
• Aurinia Pharmaceuticals Inc.: net property, plant and equipment
• Aurinia Pharmaceuticals Inc.: share-based compensation expense
• Aurinia Pharmaceuticals Inc.: operating income or loss
• Aurinia Pharmaceuticals Inc.: current assets
• Aurinia Pharmaceuticals Inc.: interest expense
• Aurinia Pharmaceuticals Inc.: current liabilities
• Aurinia Pharmaceuticals Inc.: current accounts payable
• Aurinia Pharmaceuticals Inc.: net finite-lived intangible assets
• Aurinia Pharmaceuticals Inc.: common-stock repurchase payments
• Aurinia Pharmaceuticals Inc.: operating expenses
• Aurinia Pharmaceuticals Inc.: net inventory
• Aurinia Pharmaceuticals Inc.: cost of revenue
• Aurinia Pharmaceuticals Inc.: selling, general and administrative expense
• Aurinia Pharmaceuticals Inc.: research and development expense

Inspect the source

Entity

Aurinia Pharmaceuticals Inc. / CIK 0001600620

Captured

2026-09-20T09:25:16.898Z

SEC response SHA-256

485b2322f410facf7f975635d1472ec076c5ca3ca22b945d0c8fc0591bc4e10e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001600620.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))